Chelatron Heavy Metal Therapy

Find It. Understand It. Heal It.

We test for heavy metal toxicity to identify chronic or acute exposure to toxic elements like lead, mercury, arsenic, cadmium, and aluminum.

We take a root-cause approach — focusing not just on whether heavy metals are present, but how they may be affecting detox pathways, mitochondrial health, immunity, hormones, and neurological function.

Chelation therapy is a medical treatment that utilizes specialized compounds, known as chelating agents—most commonly EDTA (ethylene diamine tetraacetic acid)—to bind and remove toxic heavy metals from the body.

These agents are typically administered either orally or intravenously, depending on the individual’s needs and the severity of the metal burden.  Once bound, these toxins are excreted through the urine, helping to reduce the body’s toxic burden.

Once in the bloodstream, the chelating agent attaches to heavy metals such as lead, mercury, arsenic, and cadmium, forming a compound that the body can safely excrete through the urine. By reducing the toxic load, chelation therapy may support the body’s natural detoxification systems, reduce oxidative stress, and improve overall metabolic and cardiovascular health.

Chelation therapy is often considered for individuals with confirmed heavy metal toxicity. Still, in specific integrative or functional medicine settings, it may also be used as part of a broader strategy to support cognitive function, reduce inflammation, or enhance overall vitality, always under the guidance of a medical professional.

This therapy is FDA-approved for treating heavy metal poisoning and iron overload disorders, such as hemochromatosis. It has a well-established track record in these areas, particularly for cases of industrial or environmental exposure to harmful metals.

Chelation therapy is also employed in integrative and functional medicine settings to support cardiovascular health, reduce systemic inflammation, and aid in managing chronic conditions such as atherosclerosis, Alzheimer’s disease, and chronic fatigue syndrome.

The NIH-funded TACT (Trial to Assess Chelation Therapy) has shown promising results for patients with heart disease.